Literature DB >> 30465775

Grand round: Autoimmune hepatitis.

Palak J Trivedi1, Stefan G Hubscher2, Michael Heneghan3, Dermot Gleeson4, Gideon M Hirschfield5.   

Abstract

Autoimmune hepatitis is a corticosteroid-responsive liver disease arising consequent to immunogenetic and environmental risk factors. The clinical course reflects relapsing and remitting, hepatocyte targeted immunologic damage, which is countered by reparative responses to cell injury. Appropriate and timely immunosuppressive therapy drives the disease into remission, albeit with inevitable side effects. Many challenges faced in the clinic reflect practice that must capture a heterogeneous disease presentation, course, and treatment response, as well as treatment tolerability. In this Grand Round we appraise the evidence supporting current treatment approaches, address the impact of autoimmune liver disease 'crossover or overlap' presentations, explore important clinical correlates to immune-serological classifiers, and discuss the factors influencing choice of alternative therapy in difficult-to-treat situations.
Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alternative therapies; Autoimmune hepatitis; Immune-mediated liver injury; Mycophenolate; Primary sclerosing cholangitis; Tacrolimus

Mesh:

Substances:

Year:  2018        PMID: 30465775     DOI: 10.1016/j.jhep.2018.11.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

Review 1.  Serum ANCA as Disease Biomarkers: Clinical Implications Beyond Vasculitis.

Authors:  Marco Folci; Giacomo Ramponi; Virginia Solitano; Enrico Brunetta
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-30       Impact factor: 10.817

2.  Better end points needed in primary sclerosing cholangitis trials.

Authors:  Alessio Gerussi; Pietro Invernizzi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

3.  Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab.

Authors:  Yuichi Honma; Michihiko Shibata; Tomonori Gohda; Hiroki Matsumiya; Keiichiro Kumamoto; Aya Miyama; Kahori Morino; Yudai Koya; Akihiro Taira; Shinji Shinohara; Tsuguru Hayashi; Masashi Kusanaga; Shinji Oe; Koichiro Miyagawa; Shintaro Abe; Fumihiro Tanaka; Masaru Harada
Journal:  Intern Med       Date:  2021-01-15       Impact factor: 1.271

4.  Predicting Liver Disease Risk Using a Combination of Common Clinical Markers: A Screening Model from Routine Health Check-Up.

Authors:  Yi Wang; Yanni Li; Xiaoyi Wang; Ranko Gacesa; Jie Zhang; Lu Zhou; Bangmao Wang
Journal:  Dis Markers       Date:  2020-05-31       Impact factor: 3.434

Review 5.  The emerging role of ferroptosis in non-cancer liver diseases: hype or increasing hope?

Authors:  Lihong Mao; Tianming Zhao; Yan Song; Lin Lin; Xiaofei Fan; Binxin Cui; Hongjuan Feng; Xiaoyu Wang; Qingxiang Yu; Jie Zhang; Kui Jiang; Bangmao Wang; Chao Sun
Journal:  Cell Death Dis       Date:  2020-07-09       Impact factor: 8.469

Review 6.  Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer.

Authors:  Yara O Aghabi; Alia Yasin; James I Kennedy; Scott P Davies; Amber E Butler; Zania Stamataki
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 8.786

7.  Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?

Authors:  Bilger Çavuş; Filiz Akyuz; Raim İliaz; Alp Atasoy; Umit Akyuz; Kadir Demir; Fatih Besisik; Sabahattin Kaymakoglu
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.219

8.  Celastrol Alleviates Autoimmune Hepatitis Through the PI3K/AKT Signaling Pathway Based on Network Pharmacology and Experiments.

Authors:  Shuhui Wang; Zheng Huang; Yu Lei; Xu Han; Dean Tian; Jin Gong; Mei Liu
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

9.  Ubiquitously specific protease 4 inhibitor-Vialinin A attenuates inflammation and fibrosis in S100-induced hepatitis mice through Rheb/mTOR signalling.

Authors:  Jie Xu; Dazhi Chen; Lanling Jin; Zhengkang Chen; Yulu Tu; Xiaozhe Huang; Feiben Xue; Jialu Xu; Mingzhuan Chen; Xiaodong Wang; Yongping Chen
Journal:  J Cell Mol Med       Date:  2020-12-09       Impact factor: 5.295

10.  The protective effect of cannabinoid type II receptor agonist AM1241 on ConA-induced liver injury in mice via mitogen-activated protein kinase signalling pathway.

Authors:  Yafeng Wu; Run Ma; Cuizhen Long; Yuanhui Shu; Ping He; Yan Zhou; Yining Xiang; Yuping Wang
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.